Improving Ebola detection devices; Varian Medical announces additional share repurchasing;

@FierceMedDev: ICYMI: FDA approves ear inserts to reduce TMJ pain. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: Intel, Michael J. Fox Foundation start smartwatch study to track Parkinson's patients. Story | Follow @StacyALawrence

@VarunSaxena2: RT @FierceMedDev: We're looking for fierce women at the top of their game in . Learn more about how to nominate. | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Top U.S. senator urges Hospira to abandon inversion plans. Article | Follow @EmilyWFierce

> New Ebola detection devices are being developed to update the arduous blood testing procedures currently necessary to properly diagnose the disease. Story

> Varian Medical ($VAR) announced an additional 6 million shares for its repurchasing plans through December 31, 2015. Release

> Nirmidas Biotech, developer of a technology platform used to detect disease biomarkers, closed a seed funding round with $2 million. Release

> Cardiovascular diagnostics company diaDexus received a $15 million loan from Oxford Finance--some of the loan will go towards paying off existing debt. Release

Biotech News

@FierceBiotech: After a few days in Copenhagen, looks like Novo's fine today amounts to dinner for 6, with wine. Report | Follow @FierceBiotech

@JohnCFierce: Norway, Denmark and now Sweden. Too bad I won't make Finland. Should be interesting to see how Stockholm has changed in the last 10 years. | Follow @JohnCFierce

@DamianFierce: $NVO's CEO on the house that Victoza built and the future of diabetes R&D. Story | Follow @DamianFierce

@EmilyMFierce: ICYMI: vaccine shows antibody response in Phase I trial. Story | Follow @EmilyMFierce

> Novartis circles back with new terms for a stem cell biotech buyout--report. More

> Struggling Eisai files its thyroid cancer drug lenvatinib in U.S., EU. News

> Novo Nordisk accepts a $90K slap on the hand for delaying news of Tresiba setback. Report

> Are they or aren't they? Chugai spurns reports of Roche takeover talks. Article

Pharma News

@FiercePharma: Top-read on FP this weekend: Bloomberg: Roche negotiating for rest of Chugai for $10B. Report | Follow @FiercePharma

@TracyStaton: Been on vacay? FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. Story | Follow @TracyStaton

@EricPFierce: ICYMI last week: Zytiga fight heats up between J&J, NICE, stirred by anxious cancer patients. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: FDA sets decision date for Pfizer's MenB candidate. More | Follow @CarlyHFierce

> Docs to FDA: Biosimilars should have different names than branded drugs. More

> Should deal-needy Pfizer target antibiotics specialist Cubist? Story

> Alabama Supreme Court redux: Pfizer can be sued for generic Reglan harms. Article

CRO News

> Shire bails out a contractor to keep its drug on the market. Report

> Evotec rides its risk-sharing model to revenue growth. Article

> AMRI swings to revenue growth amid a transitional year. News

> ABL teams up with Expression Therapeutics on a hemophilia treatment. Item

> Almac pours $90M into N. Ireland, adding 350 jobs. Story

Biotech IT News

> Validic raises $5M to fuel 'crazy' growth of data aggregation platform. News

> Top U.S. universities join project to apply Big Data to social problems. Item

> Oxford Nanopore raises $59M to scale up production of MinION sequencer. More

> Survey: Scientists talk on Twitter, network on ResearchGate. Story

> Pfizer continues to explore virtual trials with 23andMe pact. Article

Animal Health News

> Kindred Biosciences' loss grows in the face of development costs. Story

> Former Warner Chilcott CFO Paul Herendeen takes that spot at Zoetis. Item

> Sales of pet products take a dive at Central Garden & Pet. More

> Australia's Jurox launches anesthetic in U.S. two months after setting up American operations. Article

> Elanco closing former ChemGen plant, moving production to the U.K. More

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.

Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.